IP Library Granted Patent US 9,440,927
Granted Patent B2
US 9,440,927 · App. 14/344,393 · Granted Sep 13, 2016

Process for preparation of substituted 3'-hydroazino-diphenyl-3-carboxylic acid compounds

Inventors: Bhargav Krishnaji Upadhye (Aurangabad, IN); Shivaji Eknath Jagadale (Kalyan, IN); Mukesh Soni (Ajmer, IN)
Assignee: Glenmark Pharmaceuticals Limited
C07D231/46C07C251/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,440,927
App. No.
14/344,393
Granted
Sep 13, 2016
Kind
B2
Abstract

The present invention provides a process for the preparation of substituted 3′-hydrazino-biphenyl-3-carboxylic acid compounds. The present invention further provides a process for the preparation of 3′-{N′-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo -1,5-dihydro-pyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid, its intermediate compounds and pharmaceutically acceptable salts thereof.

Claims (41)

1. A process for the preparation of a substituted 3′-hydrazino-biphenyl-3-carboxylic acid compound of formula I and salts thereof,

wherein R represents hydrogen, linear or branched C 1-6 alkyl, C 3-8 cycloalkyl, optionally substituted benzyl, linear or branched alkylalkoxy, tetrahydrofuranyl, tetrahydropyranyl, medryloxybenzyl, trialkylsilyl, acyl, or trityl; the process comprising:

a) reacting a compound of formula III,

wherein R is as defined above, X is selected from the group consisting of Cl Br, and I, with a compound of formula IV,

wherein R′ represents boronic acid, boronic acid ester or halogen in the presence of a metal catalyst; and

(b) optionally, deprotecting the compound of formula I.

2. The process of claim 1 , wherein R is C 1-6 alkyl, X is Br and R′ is boronic acid.

3. The process of claim 1 , wherein R is C 1-6 alkyl, X is Br and R′ is halogen selected from the group consisting of Cl, Br, and I.

4. The process of claim I, wherein the metal catalyst is selected from the group consisting of Pd(PPh 3 ) 4 , PdCl 2 (PPh 3 ) 2 , PdCl 2 (dppf), Pd(OAc) 2 , NiCl 2 (PPh 3 ) 2 , and PdCl 2 (dppb).

5. A compound of formula III,

wherein X is selected from the group consisting of Cl, Br, and I and R represents hydrogen, linear or branched C 1-6 alkyl, C 3-8 cycloalkyl, optionally substituted benzyl linear or branched alkylalkoxy, tetrahydrofuranyl, tetrahydropyranyl, methyloxybenzyl trialkylsilyl, acyl, or trityl.

6. The compound of claim 5 , wherein X is Br and R is methyl.

7. The process of claim 1 , wherein the compound of formula III is obtained by reacting a compound of formula V,

wherein X is selected from the group consisting of Cl, Br, and I, R represents hydrogen, linear or branched C 1-6 alkyl, C 3-8 cycloalkyl optionally substituted benzyl, linear or branched alkylalkoxy, tetrahydrofuranyl, tetrahydropyranyl, methyloxybenzyl, trialkylsilyl, acyl, or trityl and R″ represents hydrogen, or a C 1-6 alkyl, with 3,4-dimethylphenylhydrazine or salt thereof to give the compound of formula III.

8. The process of claim 7 , wherein X is Br, R is methyl and R″ is ethyl.

9. The process of claim 7 , wherein the compound of formula V is obtained by reacting a compound of formula VI or its salt thereof,

wherein X is selected from the group consisting of Cl, Br, and I and R represents hydrogen, linear or branched C 1-6 alkyl, C 3-8 cycloalkyl, optionally substituted benzyl linear or branched alkylalkoxy, tetrahydrofuranyl, tetrahydropyranyl, methyloxybenzyl, trialkylsilyl, acyl, or trityl,

with alkyl acetoacetate or acetoacetic acid in the presence of an alkali or alkaline earth metal nitrite and an inorganic acid in a solvent system to yield the compound of formula V.

10. The process of claim 9 , wherein the inorganic acid is selected from the group consisting of hydrochloric acid, nitric acid, and sulfuric acid.

11. The process of claim 9 , wherein the solvent system is selected from the group consisting of methanol, ethanol, water and mixtures thereof.

12. The process of claim 1 , for the preparation of eltrombopag, a compound of formula Ia,

the process comprising subjecting the compound of formula I to a deprotection reaction,

wherein R has the aforestated meaning.

13. The process of claim 12 , herein the deprotection reaction process includes any of the following:

(a) where R is C 1-6 alkyl, C 3-8 cycloalkyl, the deprotection of the compound of formula I is performed using a protic acid; a sulphur compound; or an alkali organomide; or

(b) where R is substituted benzyl, methyloxybenzyl, the deprotection of the compound of formula I is performed via hydrogenation reaction using hydrogen in the presence of a metal catalyst; or

(c) where R is linear or branched alkylalkoxy, tetrahydrofuranyl, tetrahydromanyl, or trilyi, the deprotection of the compound of formula I is performed using an inorganic acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid; or an organic acid; or

(d) where R is trialkylsityl, the deprotection of the compound of formula I is performed using an organic acid; or

(e) where R is acyl, the deprotection of the compound of formula I is performed using an inorganic acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid; or an inorganic, base selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium carbonate, and potassium carbonate.

14. The process of claim 12 , further comprising reacting eltrombopag or a salt thereof with an excess of ethanolamine without using any additional reactor solvent.

15. The process of claim 14 , wherein the salt is eltrombopag ammonium salt.

16. The process of claim 1 , for the preparation of the compound of formula Ib,

the process comprising reacting the compound of formula III, wherein X is Br and R is methyl, with the compound of formula IV, wherein R′ is boronic acid, in the presence of a metal catalyst.

17. The process of claim 16 , further comprising deprotecting the compound of formula Ib using a Lewis acid to give eltrombopag, a compound of formula Ia

18. The process of claim 17 , wherein the Lewis acid is selected from the group consisting of aluminium chloride, aluminium bromide, aluminium iodide, stannous chloride, stannous bromide, titanium chloride, boron trifluoride, boron tribronaide, boron trifluoride-dimethylsulfide complex, beryllium chloride, beryllium bromide, zinc chloride, zinc bromide, trimethylsilylchloride, trimethylsilylbromide, and trimethylsilyliodide.

19. The process of claim 1 , wherein the deprotection reaction process includes any of the following:

(a) where R is C 1-6 alkyl, or C 3-8 cycloalkyl, the deprotection of the compound of formula I is performed using a probe acid; a Lewis acid; a sulphur compound; or an alkali organomide; or

(b) where R is optionally substituted benzyl, methyloxybenzyl, the deprotection of the compound of formula I is performed via hydrogenation reaction using hydrogen in the presence of a metal catalyst; or

(c) where R is linear or branched alkylalkoxy, tetrahydrofuranyl, tetrahydropyranyl, or trityl, the deprotectton of the compound of formula I is performed using an inorganic acid or an organic acid; or

(d) where R is trialkylsilyl, the deprotection of the compound of formula I is performed using an organic acid; or

(e) where R is acyl, the deprotection of the compound of formula I is performed using an inorganic acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid; or an inorganic base selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium carbonate, and potassium carbonate.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2019
From: GLENMARK PHARMACEUTICALS LIMITED
To: GLENMARK LIFE SCIENCES LIMITED
Reel/Frame 050179/0351 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2016
From: UPADHYE, BHARGAV KRISHNAJI; JAGADALE, SHIVAJI EKNATH; SONI, MUKESH
To: GLENMARK GENERICS LIMITED
Reel/Frame 037437/0590 →
MERGER Recorded Jan 8, 2016
From: GLENMARK GENERICS LIMITED
To: GLENMARK PHARMACEUTICALS LIMITED
Reel/Frame 037470/0628 →
Priority Claims (3)
IN 2570/MUM/2011 · Sep 13, 2011 · national
IN 2898/MUM/2011 · Oct 17, 2011 · national
IN 582/MUM/2012 · Mar 5, 2012 · national
Continuity (1)
Related Publication 20150087845A1 · Mar 26, 2015